This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
September 08, 2020
Oncopeptides further aligns the US and global organizational structure and appoints Mohamed Ladha as General Manager of the US Business Unit
September 08, 2020
Strongbridge Biopharma plc Provides Corporate Update
September 08, 2020
Strongbridge Biopharma plc Announces Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome
September 04, 2020
Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma – 495 patients included
September 03, 2020
Aprea Therapeutics to Present at Upcoming Investor Conferences
September 03, 2020
Swedish Healthtech company Doctrin expands into UK
September 03, 2020
Nordic Nanovector – Mature Data from the LYMRIT 37-01 – Part A trial, Published in Blood Advances
September 02, 2020
Targovax is invited to present at Pareto Nordic Healthcare conference and RAS-targeted drug development summit
September 01, 2020
Nordic Nanovector to Present at Upcoming Pareto Securities 11[ th ]Healthcare Conference
September 01, 2020
Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders